LMR Partners’s Humacyte HUMA Stock Holding History

LMR Partners’s Portfolio HUMA Stock Details HUMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-36,960	Closed	-$268K	–	1271
2021 Q4	$268K	Buy	+36,960	New	+$366K	﹤0.01%	1022

Other funds holding HUMA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

YCMGA

York Capital Management Global Advisors New York $87.8M AUM 45.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PGP

Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GIA

Gladstone Institutional Advisory Palm Beach Gardens, Florida $2.7B AUM 23.82% 1-Year Est. Return

LMR Partners's HUMA Position: Q1 2022 in Review

LMR Partners sold out of Humacyte (HUMA) in Q1 2022, closing a stake of 36,960 shares — an estimated $268K sold.

LMR Partners first reported a position in HUMA in Q4 2021 and held it in 1 quarter. The position peaked at $268K in Q4 2021. 70 funds tracked by Wall St. Rank hold HUMA as of Q1 2022.

LMR Partners reported no remaining Humacyte position as of Q1 2022 after selling out during the quarter.
LMR Partners sold 36,960 Humacyte shares in Q1 2022, an estimated $268K.
LMR Partners first reported a position in Humacyte in Q4 2021 and held it in 1 quarter.
LMR Partners's Humacyte position peaked at $268K in Q4 2021.
70 funds tracked by Wall St. Rank held Humacyte as of Q1 2022.

Based on LMR Partners's 13F filing for Q1 2022, filed 16 May 2022.